Overview

A Clinical Study to Evaluate the Efficacy and Safety of CKD-351

Status:
Not yet recruiting
Trial end date:
2022-05-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate efficacy and safety of CKD-351.
Phase:
Phase 3
Details
Lead Sponsor:
Chong Kun Dang Pharmaceutical
Treatments:
Latanoprost